Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II age-adjusted R-BAC induction in older patients with mantle cell lymphoma
2011-005739-23Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, bendamustine and cytarabine in mantle cell lymphoma (MCL), sponsored by Fondazione Italiana Linfomi. Primary endpoints: Complete remission rate at end of treatment and Primary safety endpoint. Started Mar 2012; status: completed.
02
Drugs
rituximabbendamustinecytarabine
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2011-005739-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005739-23.